# Curevo Vaccines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curevo-vaccines

- Industry: Biopolymers
- Headquarters: Bothell, US
- Website: www.curevovaccine.com
- Total disclosed funding: $170M
- Latest round: Series B (Mar 6, 2025)
- Investors on record: 9

## About

Founded in 2017 and based in Washington, U.S., Curevo, Inc., trading under the name Curevo Vaccine, is a clinical-stage biotechnology company specializing in the development of non-mRNA vaccines for shingles and chickenpox. In March 2025, Curevo Vaccines raised USD 110 million in series B funding led by new investor Medicxi Ventures, with participation from returning investors RA Capital Management, Janus Henderson Investors, Adjuvant Capital and GC Biopharma. As of 2022, the company is led by its CEO George Simeon Curevo uses its adjuvant biology-based sub-unit vaccine technology platform to develop vaccines for infectious diseases. As of 2022, the company’s pipeline program includes CRV-101, a vaccine being investigated in phase 1 clinical study that can prevent shingles in older adults and chickenpox in immunocompromised youngsters. The company will use the March 2025 funding to advance Amezosvatein Shingles Vaccine.

## Funding rounds

- Series B, Mar 6, 2025, $42M — OrbiMed Advisors, HBM Partners, Sanofi Ventures, RA Capital Management, Medicxi, GC Biopharma, Janus Henderson Investors, Adjuvant Capital
- Series A, Nov 10, 2022, $22M — RA Capital Management, GC Biopharma, Janus Henderson Investors, Adjuvant Capital
- Series A, Feb 10, 2022, $60M — RA Capital Management, GC Biopharma, EN Investment, Janus Henderson Investors, Adjuvant Capital
- Series A, Dec 29, 2021, $46M — RA Capital Management, EN Investment, Janus Henderson Investors, Adjuvant Capital

## Investors

- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- EN Investment — Series A
- Janus Henderson Investors — Series A, Series B
- Adjuvant Capital (https://capitalatlas.ai/funds/adjuvant-capital) — Series A, Series B
- GC Biopharma — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series B